$$$$$$‘Each of these programs offers us the opportunity to advance cancer treatment in a significant way,’ he said. Recent (November 2003) FDA guidance regarding pharmacogenomics technologies promulgate that if markers are validated using well understood markers in legitimate clinical environments, genetic tests derived from those markers should be included in new drug applications.